for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis AG

NOVN.S

Latest Trade

77.78CHF

Change

-0.38(-0.49%)

Volume

364,165

Today's Range

77.32

 - 

77.79

52 Week Range

73.01

 - 

86.92

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
78.16
Open
77.47
Volume
364,165
3M AVG Volume
86.75
Today's High
77.79
Today's Low
77.32
52 Week High
86.92
52 Week Low
73.01
Shares Out (MIL)
2,237.09
Market Cap (MIL)
191,476.40
Forward P/E
13.30
Dividend (Yield %)
3.84

Next Event

Q4 2021 Novartis AG Earnings Release

Latest Developments

More

UK's MHRA Says Maintenance Doses Of Brolucizumab Not To Be Given At Intervals Of Less Than 8 Weeks Apart

Molecular Partners Finalizes License Agreement With Novartis For Ensovibep For Covid-19

Novartis Announces Collaboration With Alnylam On Liver-Targeted Therapy

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novartis AG

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Industry

Major Drugs

Contact Info

Lichtstrasse 35

4056

Switzerland

+41.61.3241111

https://www.novartis.com/

Executive Leadership

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Vasant Narasimhan

Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

Lead Independent Non-Executive Vice Chairman of the Board

Harry Kirsch

Chief Financial Officer, Member of the Executive Committee

Steven Baert

Chief People & Organization Officer, Member of the Executive Committee

Key Stats

2.45 mean rating - 31 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

51.9K

2019

47.4K

2020

48.7K

2021(E)

52.2K
EPS (USD)

2018

5.150

2019

5.400

2020

5.780

2021(E)

6.325
Price To Earnings (TTM)
19.61
Price To Sales (TTM)
3.96
Price To Book (MRQ)
3.35
Price To Cash Flow (TTM)
13.35
Total Debt To Equity (MRQ)
60.32
LT Debt To Equity (MRQ)
43.53
Return on Investment (TTM)
10.39
Return on Equity (TTM)
7.82

Latest News

Latest News

Novartis-Molecular Partners COVID drug could be approved in weeks

Swiss drugmaker Novartis and partner Molecular Partners could have an experimental drug on the market within several weeks to treat COVID-19 patients, officials from the two companies said on Monday.

Novartis in-licenses COVID-19 treatment ensovibep from Molecular Partners

Novartis said it will license in a new drug it has been developing with Molecular Partners to treat COVID-19, the Swiss company said on Monday, after getting positive trial data.

Novartis in-licenses COVID-19 treatment ensovibep from Molecular Partners

Novartis and Molecular Partners said on Monday they had received positive topline data from a phase 2 study for ensovibep (mp0420), an antiviral therapeutic for COVID-19.

Novartis buys UK's Gyroscope for $1.5 billion to get gene therapy for eye disease

Swiss drugmaker Novartis AG is buying Gyroscope Therapeutics for up to $1.5 billion, looking to bolster its gene therapy roster with the British firm's treatment for geographic atrophy, a leading cause of blindness.

Novartis to buy Gyroscope Therapeutics for up to $1.5 bln

Healthcare investment firm Syncona Ltd said on Wednesday Novartis AG will buy its Gyroscope Therapeutics unit for up to $1.5 billion as the Swiss drugmaker seeks access to the British firm's gene therapy for a blindness-causing disease. (Reporting by Sinchita Mitra and Pushkala...

Novartis options BeiGene anti-cancer therapy in $1 billion deal

Novartis has signed an option, collaboration and licence agreement with BeiGene Ltd for anti-cancer therapy ociperlimab (BGB-A1217) to expand its activities in immuno-oncology, the Swiss drugmaker said on Monday.

Novartis says ligelizumab suffers setback in late-stage studies

Swiss drugmaker Novartis said on Monday its ligelizumab antibody treatment against recurring hives did not meet the goal of superiority to standard treatment omalizumab in a late-stage study.

Cash-flush Novartis launches new share buyback of up to $15 billion

Novartis AG is launching a new share buyback worth up to $15 billion to be executed by the end of 2023, it said on Thursday, adding it was confident in its top-line growth and deep pipeline.

Novartis launches new share buyback of up to $15 bln

Novartis AG said on Thursday it was launching a new share buyback of up to $15 billion to be executed by the end of 2023, adding it was confident in its top line growth and deep pipeline.

Novartis Pharma, Kaiser Permanente look to their own for new top lawyers

Novartis Pharmaceuticals and Kaiser Permanente both promoted attorneys from within this week to lead their legal departments.

Novartis sees strong interest in Sandoz generics unit - Finanz und Wirtschaft

Novartis is seeing strong interest from private equity investors as well as from other pharmaceuticals companies for the Sandoz generic drugs business it is considering selling, Chief Executive Vas Narasimhan said in a newspaper interview.

Novartis CEO says Sandoz attracting interest - paper

Novartis's potential sale of its Sandoz generic drug business is attracting interest from possible buyers, Chief Executive Vas Narasimhan said in an interview to be published on Friday.

Novartis working on pan-coronavirus oral treatment, CEO says

Novartis hopes to still play a role in the development of COVID-19 treatments with research ongoing for a pill that could work broadly against coronaviruses, not just the one that causes COVID-19, chief executive Vas Narasimhan told Reuters.

Novartis CFO says shareholders pushing for large share buyback

Novartis finance chief Harry Kirsch said on Thursday that around half of the Swiss pharmaceutical company's investors were urging it to go through with a share buyback of significant size.

Novartis expects new drugs to boost sales by at least 4% until 2026

Novartis is confident of delivering annual revenue growth of 4% or higher until 2026, as it banks on multi-billion dollar sales of experimental and approved drugs including arthritis and psoriasis medicine Cosentyx.

Novartis chairman says all options open for Sandoz unit - report

Novartis is keeping all options open for the future of its generics division Sandoz, its chairman said in an interview with Swiss TV channel TeleZüri to be broadcast on Tuesday.

Roche shareholders approve deal to buy Novartis's $20.7 billion stake

Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.

Roche shareholders approve deal to buy Novartis's stake

Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.

EQT, BioNTech investor consider bid for Novartis arm Sandoz -report

Investment group EQT and the Struengmann family, who are investors in BioNTech, are considering a joint offer for Sandoz, the generics arm of Swiss drugmaker Novartis, Handelsblatt reported on Friday.

Roche chairman sees greater flexibility after Novartis deal - paper

Roche's $20.7 billion move to buy back nearly a third of its voting stock from fellow Swiss drugmaker Novartis will give it more strategic flexibility, Chairman Christoph Franz said in an interview published on Saturday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up